OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Registration to our newsletter is FREE, Join today by entering your email below!

Tag Archives: cancer drug

Can Dendreon Corporation (NASDAQ: DNDN) Fight Off Competition and Rebound from Disappointing First Quarter?

Investors who have been trying to get an accurate read on what’s happening with Dendreon Corporation (NASDAQ: DNDN) have no doubt been frustrated by the inconsistency of the biotechnology company’s share price as it has experienced considerable shifts over the … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Has Dendreon Corp.’s (NASDAQ: DNDN) Time to Shine Finally Arrived?

It would be safe to say that several investors have lost a considerable amount of sleep, as well as money, in their dealings with Dendreon Corp. (NASDAQ: DNDN) as the biotechnology company has hit highs near the $60 level while … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , | Leave a comment

Is Fuse Science, Inc. (OTCQB: DROP) Overly Optimistic About their Patchless Delivery Technology for Medicines, Vitamins and Minerals?

Trading activity surrounding Fuse Science, Inc. (OTCQB: DROP) continues to hit high marks as the holding company that “holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals” has already seen 7.2 … Continue reading

Posted in Uncategorized | Tagged , , , , , , , | Leave a comment

Can Investors Capitalize Off Misfortunes of Dendreon Corp. (NASDAQ: DNDN)?

One year ago shares of Dendreon Corp. (NASDAQ: DNDN) were trading at a 52-week high of 37.19 and the darling of the biotechnology industry with a prostate cancer drug on the market that was almost certainly going to bring in … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , | Leave a comment

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) Generating Buzz Following Article Highlighting Prospect of FDA Approval for Perifosine

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) spiked to a six-month high of 5.12 on Monday following a article claiming an FDA approval for the cancer drug Perifosine was all but guaranteed but by Tuesday morning the buying frenzy slowed and shares … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment